https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.twMain Products/ Pipelines & Platforms
This product is a monoclonal antibody targeting misfolded TDP-43 oligomers to treat ALS and TDP-43 proteinopathies, including FTD and AD, without affecting native TDP-43. TDP-43 proteinopathies are present in 95% of ALS, 50% of FTD, and 30–57% of AD cases, all of which lack effective treatments. In ALS mouse models, the antibody improved motor neuron survival, motor behavior, neuromuscular junction reinnervation, reduced TDP-43 oligomer levels, and decreased inflammation. The antibody’s humanization is complete, making it a first-in-class therapeutic for ALS.
Indications & Development Stages Amyotrophic Lateral Sclerosis (ALS): Currently in preclinical development. Frontotemporal Dementia (FTD) & Alzheimer’s Disease (AD): Both are in the lead optimization stage. Plasma/CSF Biomarker Detection: Undergoing preclinical development.
Business Interests
Out-Licensing, Co-Development
Contact Info
Wei-Wei Chang
Postdoctoral fellow
+886-2-2789-8780
wwchangym@gmail.com